Considerable progress was made at the meeting of the InternationalConference for Harmonization Steering Committee and its technical working groups in Chiba, Japan, in late May, on the regional implementation plans for submissions to be made in the Common Technical Document format. From July 2003, submission in the CTD format will be expected in the USA and mandatory in both the EU and Japan.
The Steering Committee signed a Step 2 for testing of the electronic CTD. Real-case testing of the eCTD by all parties will now go ahead, and definitive Step 2 documents on the eCTD are expected to be signed off in October in Brussels, Belgium.
A satellite meeting on biotechnological and gene therapy products noted the need to continue fostering the exchange of information under ICH auspices in relation to emerging scientific information on such products. Dose definition and standardization, virus shedding and germ-line integration were identified as ICH priorities, and it was recommended that a workshop be held in Washington DC, USA, next spring to review technical issues related to dose definition and standardization.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze